As a chemical biologist, Texas A&M University chemist Wenshe Ray Liu has a vested interest in preliminary results from a University of Chicago clinical trial using the experimental drug remdesivir to treat patients suffering from COVID-19.
Liu was the first person to identify the Gilead Sciences-developed antiviral as the only viable medicine for treating COVID-19 in a January research study. At the time, he believed so strongly in its singular effectiveness that he refocused his entire research group from cancer to COVID-19, challenging them to find additional drugs capable of combatting the novel coronavirus pandemic then rapidly spreading across [...]
